WuXi PharmaTech has signed a new three-year collaboration agreement with AstraZeneca, expanding a two-year, $14 million collaboration from April 2006 under which WuXi delivered more than 100,000 compounds ahead of schedule. Under the new agreement, WuXi PharmaTech will synthesize compounds, according to AZ’s designs, which will further expand AZ’s global compound collection.     “This new collaboration agreement further strengthens our already productive relationship with A...